Oral drugs may protect cancer patients from blood clots
London, May 13: Taking oral drugs daily can be an effective treatment for nearly 10 million cancer patients worldwide suffering from a deadly blood clot condition, results from a clinical trial have showed.
People with cancer have an increased risk of developing blood clots, with roughly one in five experiencing venous thromboembolism (VTE) -- either a blood clot in a deep vein or a condition in which one or more arteries in the lungs become blocked by a blood clot.
The results from the clinical trial called "select-d" suggested that prescribing the oral drug rivaroxaban significantly reduced VTE recurrence among patients with cancer.
"Clinicians were already adopting the oral drug into practice for non-cancer patients and now they have data from this study to indicate that this form of treatment is an alternative option for many cancer patients who have a clot," said lead author Annie Young, Professor at University of Warwick in the Britain.
Although there are many causes and risk factors for VTE, cancer patients are particularly at risk due to a combination of factors such as immobility, pancreatic and gastric tumours as well as chemotherapy, the researcher said.
For the "select-d" trial, researchers enrolled 406 patients who had cancer and VTE; most (69 per cent) were receiving cancer treatment (typically chemotherapy) at the time of their VTE.
Half were randomly assigned to receive low-molecular-weight heparin (dalteparin) and half were given the oral drug rivaroxaban. After six months of treatment, the VTE recurrence rate was four per cent among those taking the tablet and 11 per cent in those receiving dalteparin.
The results for secondary outcomes were mixed, the researcher said.
In patients receiving rivaroxaban, there were around the same percentage of major bleeding events (6 per cent) as those receiving dalteparin (4 per cent) but a marked and significant increase in clinically relevant non-major bleeds (13 per cent) with rivaroxaban compared to those having low molecular weight heparin (4 per cent).
The reason for increased bleeding is not known. It may be because rivaroxaban is more 'potent', the paper published in the Journal of Clinical Oncology said.
Let the Truth be known. If you read VB and like VB, please be a VB Supporter and Help us deliver the Truth to one and all.
10-year-old boy stuck in borewell in MP's Guna, rescue operation on
Bhopal, Dec 28: A 10-year-old boy fell into an open borewell in Madhya Pradesh's Guna district on Saturday evening and a rescue operation was underway, officials said.
The incident took place in Raghogarh area.
Sumit Meena, the boy, slipped into the open shaft of the borewell at Pipliya village, about 50 km from Guna district headquarters, about 5 pm.
He was trapped at a depth of around 39 feet, Raghogarh Congress MLA Jaivardhan Singh told PTI from the spot.
A parallel pit has been dug to rescue him, he said.
While police started the rescue operation immediately, a team of the National Disaster Response Force (NDRF) had also arrived from Bhopal, the MLA said.
Oxygen was being pumped into the borewell, he said.
